Literature DB >> 7911050

Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene.

C M Eng1, R J Desnick.   

Abstract

Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the alpha-galactosidase A gene at Xq22.1. Studies of the mutations in unrelated Fabry families have identified a variety of lesions indicating the molecular genetic heterogeneity underlying the disease. Forty-nine different mutations have been described including five partial gene deletions, one partial gene duplication, nine small deletions and insertions, three splice junction consensus site alterations, and 31 coding region single base substitutions. Most mutations resulted in the classical disease phenotype; however, five missense mutations were detected in atypical hemizygotes who were asymptomatic or had symptoms confined to the heart, including N215S, which was described in three unrelated atypical males. Most mutations were confined to a single pedigree with the exception of N215S, R227Q, R227X, R342Q, and R342X, which were each found in several unrelated families. Five of the 14 coding region CpG dinucleotides were sites of point mutations including the CpGs in codons 227 and 342, which were each mutated in both orientations. The identification of the mutation in a given Fabry family permits precise prenatal diagnosis and heterozygote detection of other family members with this X-linked recessive disease. Studies of additional Fabry families will provide information on the nature and frequency of the mutations causing this disease as well as potential insights into the structure/function relationships of this lysosomal hydrolase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911050     DOI: 10.1002/humu.1380030204

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  39 in total

1.  α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.

Authors:  Aleksandra Siekierska; Greet De Baets; Joke Reumers; Rodrigo Gallardo; Stanislav Rudyak; Kerensa Broersen; Jose Couceiro; Joost Van Durme; Joost Schymkowitz; Frederic Rousseau
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

2.  Human alpha-galactosidase A: high plasma activity expressed by the -30G-->A allele.

Authors:  T F Fitzmaurice; R J Desnick; D F Bishop
Journal:  J Inherit Metab Dis       Date:  1997-09       Impact factor: 4.982

3.  Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.

Authors:  L B Jardim; I Gomes; C B O Netto; D B Nora; U S Matte; F Pereira; M G Burin; L Kalakun; R Giugliani; J Becker
Journal:  J Inherit Metab Dis       Date:  2006-07-27       Impact factor: 4.982

Review 4.  Cardiac manifestations in Fabry disease.

Authors:  A Linhart; J C Lubanda; T Palecek; J Bultas; D Karetová; J Ledvinová; M Elleder; M Aschermann
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

5.  Editing of human alpha-galactosidase RNA resulting in a pyrimidine to purine conversion.

Authors:  F J Novo; A Kruszewski; K D MacDermot; G Goldspink; D C Górecki
Journal:  Nucleic Acids Res       Date:  1995-07-25       Impact factor: 16.971

Review 6.  Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia.

Authors:  S S Bottomley; B K May; T C Cox; P D Cotter; D F Bishop
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

7.  Novel trinucleotide deletion in Fabry's disease.

Authors:  M A Cariolou; M Christodoulides; P Manoli; A Kokkofitou; D Tsambaos
Journal:  Hum Genet       Date:  1996-04       Impact factor: 4.132

Review 8.  The proteolipid protein gene: double, double, ... and trouble.

Authors:  M E Hodes; S R Dlouhy
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

9.  Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.

Authors:  I Redonnet-Vernhet; J K Ploos van Amstel; R P Jansen; R A Wevers; R Salvayre; T Levade
Journal:  J Med Genet       Date:  1996-08       Impact factor: 6.318

10.  Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility.

Authors:  Y A Ioannou; K M Zeidner; M E Grace; R J Desnick
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.